← Human Trials & Peer-Reviewed Studies
Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial
Plain-language guide to PMID 12190367 (2002): double-blind randomized controlled trial of Cyanocobalamin (Vitamin B12) in 553 patients.
Key Facts
- PMID
- 12190367
- Journal
- JAMA
- Year
- 2002
- Study type
- Randomized Controlled Trial
- Authors
- Schnyder G et al. (5 authors)
- DOI
- 10.1001/jama.288.8.973
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Cyanocobalamin (Vitamin B12).
To evaluate the effect of homocysteine-lowering therapy on clinical outcome after percutaneous coronary intervention.
Why It Was Studied
Plasma homocysteine level has been recognized as an important cardiovascular risk factor that predicts adverse cardiac events in patients with established coronary atherosclerosis and influences restenosis rate after percutaneous coronary intervention.
Who Took Part
The study group was 553 patients.
PubMed indexes the participants as middle-aged adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this Cyanocobalamin (Vitamin B12) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the patients and researchers unaware of who received Cyanocobalamin (Vitamin B12).
The comparison arm used a placebo, so changes seen with Cyanocobalamin (Vitamin B12) could be set against what happens without it.
What Was Measured
Plasma homocysteine level has been recognized as an important cardiovascular risk factor that predicts adverse cardiac events in patients with established coronary atherosclerosis and influences restenosis rate after percutaneous coronary intervention.
Topics PubMed links to this paper include Angioplasty, Balloon, Coronary, Coronary Angiography, Coronary Stenosis, Folic Acid, Homocysteine, Vitamin B 12 and Vitamin B 6.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Cyanocobalamin (Vitamin B12) in 553 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2002 (JAMA), a journal based in United States.
More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.
Our Notes on the Compound
Cyanocobalamin (Vitamin B12): A synthetic form of vitamin B12 (cobalamin), an essential nutrient for DNA synthesis, red blood cell formation and neurological function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.